Effects of combined treatment with trimetazidine and atorvastatin on myocardial protection of patients undergoing percutaneous coronary intervention

Abstract

Objective: To evaluate the myocardial protection effects of combined treatment with trimetazidine and atorvastatin on patients undergoing percutaneous coronary intervention(PCI).Methods: Three hundred and twenty-three patients with acute coronary syndrome were enrolled and randomly divided into test group(n=161) and control group(n=162).Patients in the test group were given trimetazidine hydrochloride 20 mg three times per day and atorvastatin calcicum 20 mg per night.Patients in the control group were given the same dose of atorvastatin calcicum.The treatment lasted 3 d before PCI.The activities of creatinine kinase-MB isoenzyme(CK-MB) and myeloperoxidase(MPO),the levels of cardiac troponin I(cTnI) and high sensitivity C reactive protein(hs-CRP) were determined.Left ventricular ejection fraction during 4 weeks after PCI were determined.Results: There was significant difference in the serum levels of cTnI at 24 h after PCI between control group and test group(P0.05).The degree of MPO activity elevation in test group was significantly lower than that in control group(P0.05).There was no significant difference in the serum activity of CK-MB and level of hs-CRP at 24 h after PCI between control group and test group(P0.05).Conclusion: The combined treatment with normal dose of trimetazidine hydrochloride and atorvastatin calcicum 3 days before PCI has a protective effect against myocardial damage.